Terns Pharmaceuticals Inc Up 7.15% To $7.19 After Earnings Meet

Friday, March 15, 2024 - Terns Pharmaceuticals Inc (TERN) reported in line earnings and revenues today.

Analyst expectations for Terns Pharmaceuticals Inc earnings per share (EPS) were at a loss of $0.29 per share, with the company missing those estimates with a reported EPS loss of $0.29 per share, leading to a neutral surprise of $0 per share. Terns Pharmaceuticals Inc's earnings were down 0% year-over-year as the firm reported an EPS loss of $0.29 per share in its year-ago quarter. The neutral annual growth shows the Healthcare company is performing neutrally amid recent economic conditions.

Terns Pharmaceuticals Inc reported a revenue of $0.00 in Q4 2023. The firm managed 0% growth year-over-year due to Terns Pharmaceuticals Inc reporting quarterly revenue of $0.00 in its year-ago quarter. Terns Pharmaceuticals Inc achieved a lower earnings growth rate than revenue, signaling that the business has not been able to improve its profit margin.

The stock is up 7.15% to $7.19 after the report.

The firm's higher revenue growth to earnings signals that the firm has not been able to reduce costs and has seen its profit margin decrease.

Wall Street Analysts had an average rating of Strong Buy on the stock prior to the report.

Trading in the five days leading up to the report earned Terns Pharmaceuticals Inc a Bearish Sentiment Rank from InvestorsObserver.

Prior to the report, InvestorsObserver gave the stock an overall score of 67. Meanwhile, the average Wall Street analyst rated the stock a Strong Buy.

Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases.